^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

PLEK2 (Pleckstrin 2)

i
Other names: PLEK2, Pleckstrin 2, Pleckstrin-2, Pleckstrin 2 Homolog
Associations
Trials
2ms
Integrative Analysis of Multi-source Public Databases to Screen Core Genes for Constructing A Prognostic Risk Model in Lung Adenocarcinoma (PubMed, Zhongguo Fei Ai Za Zhi)
The risk model constructed in this study effectively predicts the prognosis of LUAD patients. PLEK2 is highly expressed in LUAD and associated with EGFR-TKIs resistance, suggesting its potential as a prognostic biomarker and therapeutic target.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • HMGA1 (High Mobility Group AT-Hook 1) • ID3 (Inhibitor Of DNA Binding 3, HLH Protein) • PLEK2 (Pleckstrin 2)
|
TP53 mutation • KRAS mutation
4ms
The immune infiltration and prognostic significance of complement and coagulation cascade-related genes in lung adenocarcinoma. (PubMed, Discov Oncol)
This prognostic model constructed based on CCCR genes represents a valid tool for the prognosis of LUAD patients. Our findings provide valuable insights into the prognostic and immunological relevance of CCCR genes in LUAD, offering a robust foundation for personalized treatment strategies and future research.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • EREG (Epiregulin) • IGFBP1 (Insulin Like Growth Factor Binding Protein 1) • PLEK2 (Pleckstrin 2)
4ms
Mechanistic study of the role of Pleckstrin-2 in glycolysis, migration and invasion of breast cancer cells. (PubMed, Biochem Biophys Res Commun)
In conclusion, our study highlights the pivotal role of PLEK2 in BC cell dynamics and introduces HOXD9 as a novel regulator of PLEK2. Targeting the HOXD9/PLEK2/AKT signaling axis may offer a promising therapeutic strategy for treating breast cancer.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • PLEK2 (Pleckstrin 2)
6ms
Integrating single-cell RNA sequencing and spatial transcriptomics to reveal the Glycolysis-related gene GPRC5A as a potential biomarker for gastric cancer by machine learning. (PubMed, Int J Biol Macromol)
This study proposes a glycolysis assessment strategy based on the interquartile range, which effectively addresses the limitations of previous scoring methods, including insufficient resolution and limited robustness. The proposed method enables more accurate quantification of intracellular glycolysis levels and facilitates fine-grained characterization of metabolic states. Furthermore, it identifies GPRC5A as a potential biomarker for the early diagnosis of gastric cancer. These findings enhance our understanding of metabolic reprogramming in gastric cancer and provide support for targeting the glycolytic pathway in therapeutic interventions.
Journal
|
CLDN1 (Claudin 1) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2) • CLDN3 (Claudin 3) • GPRC5A (G Protein-Coupled Receptor Class C Group 5 Member A) • PGK1 (Phosphoglycerate Kinase 1) • PLEK2 (Pleckstrin 2)
7ms
Pleckstrin-2 promotes the progression of colorectal cancer via YTHDF2-mediated TYMS mRNA stability. (PubMed, Cell Mol Life Sci)
High expression of nucleotide synthetic enzyme thymidylate synthase (TYMS) is responsible for the resistance to fluorouracil (FU) treatment and worse survival in colorectal cancer (CRC)...PLEK2 inhibition is sufficient to ameliorate the progression of AOM/DSS-induced CRC. Together, our study identified PLEK2 as a key regulator for the progress of CRC via the regulation of TYMS expression, and demonstrated that PLEK2 is a novel therapeutic target for CRC.
Journal
|
TYMS (Thymidylate Synthetase) • PLEK2 (Pleckstrin 2) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
5-fluorouracil
8ms
Development of a machine learning-derived dendritic cell signature for prognostic stratification in lung adenocarcinoma. (PubMed, Front Immunol)
We established a novel DCRS with robust prognostic and predictive value in LUAD. This work highlights the pivotal role of dendritic cell programs in shaping the tumor microenvironment and provides potential targets for improving precision immunotherapy.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • PLEK2 (Pleckstrin 2)
10ms
PPIL2 is a target of the JAK2/STAT5 pathway and promotes myeloproliferation via p53-mediated degradation. (PubMed, J Clin Invest)
Cyclosporin A also markedly reduced JAK2 mutated erythroid and myeloid proliferation in an induced pluripotent stem cell-derived human bone marrow organoid model. Our findings revealed PPIL2 as a critical component of the PLEK2 signalosome in driving MPN pathogenesis through negatively regulating p53, thus providing a target and an opportunity for drug repurposing by using cyclosporin A to treat MPNs.
Journal
|
PLEK2 (Pleckstrin 2)
|
cyclosporin A microemulsion
11ms
Machine learning‑based construction of damage‑associated molecular patterns related score identifies subtypes of pancreatic adenocarcinoma with distinct prognosis. (PubMed, Oncol Lett)
In conclusion, the DAMPscore is a promising prognostic biomarker for PAAD, surpassing traditional models in various datasets. This study emphasizes the role of DAMP-related pathways in influencing tumor biology and highlights the importance of immune modulation in PAAD prognosis, suggesting that therapeutic strategies targeting DAMP signaling could improve patient outcomes.
Journal
|
PLEK2 (Pleckstrin 2)
1year
CircCNKSR2 Facilitates NSCLC Tumorigenesis and Warburg Effect via miRNA-138-5p/PLEK2 Axis. (PubMed, Crit Rev Eukaryot Gene Expr)
Additionally, PLEK2 identified as a miR-138-5p target gene. The potential regulatory role of circCNKSR2 in NSCLC progression and Warburg effect via the miR-138-5p/PLEK2 pathway was demonstrated.
Journal
|
MIR138 (MicroRNA 138) • PLEK2 (Pleckstrin 2)
1year
PLEK2: a potential biomarker for metastasis and prognostic evaluation in uveal melanoma. (PubMed, Front Med (Lausanne))
PLEK2 is upregulated in UVM and correlates with poor patient prognosis, likely influencing the calcium signaling pathway. PLEK2 represents a promising prognostic biomarker and therapeutic target for UVM.
Journal
|
PLEK2 (Pleckstrin 2)
over1year
Unveiling the role of Pleckstrin-2 in tumor progression and immune modulation: insights from a comprehensive pan-cancer analysis with focus on lung cancer. (PubMed, Mol Biomed)
Compounds like Navitoclax were also identified as potential PLEK2 inhibitors. In conclusion, PLEK2 played a multifaceted role in cancer progression and immune response modulation. Targeting PLEK2 might suppress tumor growth and overcome immunotherapy resistance, offering a promising biomarker and therapeutic target to improve cancer treatment outcomes.
Journal • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
CD8 (cluster of differentiation 8) • PLEK2 (Pleckstrin 2)
|
navitoclax (ABT 263)
over1year
PLEK2 promotes migration and invasion in pancreatic ductal adenocarcinoma by MMP1 through IL-17 pathway. (PubMed, Mol Cell Biochem)
Overall, the present study suggests that PLEK2 may play a tumor-promoting role in PDAC. These findings provide valuable insights into the molecular mechanisms of pancreatic cancer and highlight the potential of PLEK2 as a therapeutic target.
Journal
|
EGFR (Epidermal growth factor receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A) • MMP1 (Matrix metallopeptidase 1) • PLEK2 (Pleckstrin 2)